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Periodontitis is an inflammatory disease caused by the imbalance between host 
immune response and bacterial infection. Strategies to manage the uncontrolled, 
excessive immune response and to promote tissue healing are in great demand. 
Therapies based on mesenchymal stem cells (MSCs) are promising and the clinical 
effects of MSCs are largely mediated by their secretome, especially exosomes. 
Previously, we isolated and purified exosomes secreted by human bone marrow 
mesenchymal stem cells (hBMSC). These exosomes have proliferative, chemotactic, 
anti-inflammatory and anti-osteoclastic function in vitro. In this study, we had two 
hypotheses: 1) hBMSC exosomes would prevent periodontal inflammation and alveolar 
bone loss with immunomodulatory function; 2) hBMSC exosomes would enhance 
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periodontal tissue regeneration. To test these hypotheses, we used a rodent ligature-
induced experimental periodontitis model. In the preventative experiment, rats were 
treated with hBMSC exosomes concurrently with ligature placement. In the regenerative 
experiment, rats were treated with hBMSC exosomes for 3 weeks and 6 weeks after the 
experimental periodontitis was induced. Our results show that, in the preventive study, 
hBMSC exosome treatment led to less disease progression as evidenced by increased 
alveolar bone volume, decreased linear bone loss, and less lymphocyte infiltration in the 
subepithelial area. However, through micro-CT and gene expression analyses, no 
significant differences were seen between the exosome treatment and control in the 
regenerative study at both time points. In summary, hBMSC exosomes can ameliorate 
the development of periodontitis via an immunomodulatory effect. However, more 












CHAPTER 1: INTRODUCTION 
 
 
1.1. PERIODONTAL DISEASE 
Periodontal disease is one of the most prevalent inflammatory diseases (1). 
Periodontal disease refers to the inflammatory process in response to the overgrowth of 
dental plaque caused by dysbiosis of bacteria complex, which often results in alveolar 
bone loss, tooth mobility and finally loss of the affected tooth (2). According to Centers 
for Disease Control and Prevention (CDC), one out of every two American adults aged 
30 and over has periodontal disease (3). Progression of periodontal disease can be 
unrecognized for a long time due to its slow and painless nature. Disease progression 
may have begun at younger age, but people often are first aware of the periodontal 
disease at older age when the irreversible damage has already been done. The 
prevalence of periodontal disease increases with age (4, 5). With more people living 
longer, the number of people developing periodontal disease will increase even more 
(6). In addition to increased prevalence in older age and detrimental effects on 
periodontal tissue, chronic periodontitis is associated with other systemic disease such 
as atherosclerosis, pneumonia, rheumatoid arthritis, adverse pregnancy outcome, 
diabetes and cancer (7-15).  Periodontitis can also have a significant effect on the 
psychosocial well‐being, as the disease causes the discomfort, food intake difficulty and 
changes in facial appearance. With physical impairment and psychological distress, 
periodontitis has a negative impact on life quality.  
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1.2 PATHOGENESIS OF PERIODONTAL DISEASE 
Host immune response plays a central role in the periodontal disease 
pathogenesis. In healthy condition, periodontal tissues are able to manage the bacterial 
infection with the controlled host immune response. When the balance between the 
control mechanism and bacterial infection is lost, disease progresses and it leads to the 
periodontal tissue damage.  
Bacteria colonize plaque biofilms on the tooth surface and initiate inflammatory 
responses (16). Firm attachment of the plaque on the tooth surface makes it impossible 
for the host immune system to remove pathogens and continue to insult the periodontal 
tissues (17). Junctional epithelium is the first periodontal structure to encounter bacterial 
pathogens which can further cross the junctional epithelium and penetrate into the 
underlying connective tissue (18). Resident cells detect the molecular pattern 
associated with pathogens (PAMPs) such as lipopolysaccharide (LPS) and Toll-like 
receptors on the cells bind with PAMP causing the activation of proinflammatory 
transcription factors, such as NFκB and AP-1 (19, 20), and the subsequent synthesize 
and release of inflammatory cytokines. Once the inflammation has been initiated, 
marginal periodontal ligament fibers are destroyed as a result of increased proteinase 
production and activity in the host immune system and therefore periodontal pockets 
are formed. Bacterial plaques spread apically along the root surface and deepen the 
pocket. The junctional epithelial cells are stimulated to proliferate and apically migrate 
along the root (21). 
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Gingival blood vessels below the junctional epithelium become inflamed. 
Neutrophils exit the post-capillary venules and migrate into the gingival sulcus (22). 
Neutrophils can recruit T-helper 17 cells (Th17) to the infection site and more 
proinflammatory cytokines are produced. In addition, they promote the accumulation of 
B cells and plasma cells which express RANKL, a key osteoclastogenic cytokine, to 
induce bone resorption (23).  
Macrophages polarize into two distinct phenotypes, M1 and M2. M1 
macrophages are induced by the LPS of microorganism or by the Th1 related cytokines 
like IFN-γ, and secrete inflammatory cytokines such as TNF-α, IL-1β, IL-6 (24). M1 
macrophages can phagocytize microorganisms and promote inflammatory response, 
which contributes to the degradation of the collagen matrix in connective tissue (25). M2 
macrophages are induced by the stimulation of Th2 related cytokines such as IL-4 and 
IL-13. They inhibit the inflammatory process by the secretion of anti-inflammatory 
cytokines including IL-10. Also, they can secrete TGF-β to promote cell proliferation and 
tissue regeneration (26). M1 rather than M2 macrophages predominate in the 
progression of chronic periodontitis (27). 
Lymphocytes are activated by two types of signals and invade into periodontal 
tissue: one is the activation of antigen receptor of lymphocytes themselves and the 
other is the antigen-presenting cells, APC. Activated lymphocytes are the main source 
of RANKL, which induces osteoclastogenesis (28). RANKL/OPG/RANK system 
manages the balance of alveolar bone metabolism (29). RANKL binds to the receptor 
RANK on the surface of osteoclast or osteoclast precursor. The binding triggers 
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osteoclasts to accumulate on the bone surface. OPG inhibits the biological functions of 
RANKL as a decoy ligand for RANK (30). Th1 lymphocytes also secrete inflammatory 
cytokines such as TNF-α and IL-1β, which cooperates with Th17 lymphocytes in 
producing RANKL. Overall, lymphocytes have an important role in the progression of 
periodontitis and bone resorption (31, 32).   




Figure 1:  Immune response during periodontal disease (description in the text). 
Source: (Muñoz-Carrillo et al., 2019)  
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    Current treatments of periodontal disease are divided into non-surgical 
treatment and surgical treatment. Traditional treatments focus on the mechanical 
debridement procedures such as scaling and root planing and allow the periodontal 
tissue to restore itself (33). Complete elimination of bacterial biofilm with mechanical 
debridement procedures is usually unachievable because of the difficulty in accessing 
deep and tortuous pockets (34). Bacteria would recolonize within a week and infection 
will continue to thrive (35). Systemic antibiotics can be used along with the mechanical 
procedures in certain patients to improve the treatment efficacy. However, systemic 
antibiotics should be used with caution as unnecessary use can develop antibiotic 
resistance (36).   
Periodontal surgical treatments focus on the elimination of periodontal pockets 
and the regeneration of periodontal apparatus. Pocket reduction surgery is a 
conservative procedure which reduces the soft tissue of periodontal pockets and 
creates new epithelial attachment with open access and debridement (37). The 
regeneration of periodontium can be accomplished with surgical treatments such as 
guided tissue regeneration and bone grafting. Although restoration to the original 
periodontal condition is not often achieved (38), periodontal surgical treatments can still 
be beneficial to people with severe periodontitis. In effort to overcome the limitations of 
current treatments, such as unpredictable outcome, sophisticated and complex 
procedures and high cost, researchers are searching for new therapies for periodontal 
regeneration.   
1.4 REGENERATION POTENTIAL OF MESENCHYMAL STEM CELLS 
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Adult mesenchymal stem cells (MSCs) are capable of multilineage differentiation 
and self-renewal (39, 40). Bone marrow is the most common source for MSCs while 
they exist in almost all tissues. Human bone marrow stem cells (hBMSCs) have been 
widely used for tissue regeneration and cell-based therapies because of their 
therapeutic effects. MSCs have the ability to migrate to the inflammation site and the 
potential to differentiate into various cell types. Once activated, they can secrete anti-
inflammatory molecules to suppress excessive inflammation and have 
immunomodulatory functions (41).  
Past research has reported up to 20% of cementum and alveolar bone 
regeneration after MSC treatment in experimental defects in dogs (42). Also, positive 
clinical results were obtained in a small clinical trial (43). The amount of MSCs in the 
bone marrow is very low (44) while a large number of cells are required for clinical 
applications. Expansion in vitro is essential to obtain the adequate amount of cells. 
However, long-term culture and higher passages can lead to cell transformation and 
decrease in differentiation ability (45-47). While MSCs appear to have high regeneration 
potential, many challenges remain for their clinical application (48).   
1.5 MSC DERIVED EXOSOMES 
Exosomes are specific extracellular vesicles (EVs) secreted into extracellular 
fluid by all cells acting as messengers to communicate with other cells. Exosomes are 
nanoscale lipid bilayer EVs that carry lipids, mRNA, miRNA and proteins derived from 
the parental cell (49, 50).  EVs are classified into three subtypes: exosomes, 
microvesicles (MVs), and apoptotic bodies (51, 52). Biogenesis process of exosomes 
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consists of four phases: initiation, endocytosis, multivesicular body (MVB) development, 
and release (53). Endosome is formed with endocytosis from the plasma membrane. 
Inward budding of endosome leads to the formation and accumulation of intraluminal 
vesicles inside the lumen developing MVB. MVB merges with the plasma membrane to 
release intraluminal vesicles into the extracellular space, which are called the exosomes 
(54).     
 
 
Figure 2: Endocytosis vesicle is formed from the plasma membrane which develops 
into late endosome. MVB is formed with inward budding in the cytosol from the 
endosome. Intraluminal vesicles in the MVB are released into extracellular space 




Exosomes contain plasma, cytosolic and nuclear proteins (55). Alix and TSG101 
proteins are associated with exosome biogenesis, and RAB proteins, Annexins, 
integrins, major histocompatibility complex (MHC), tetraspanins are associated with 
membrane function (56). Tetraspanins such as CD9, CD81, CD82 and CD63 are 
involved in cellular interactions through binding with integrins and MHC (57). HSP70 
and HSP90 are common cargo proteins (58). The associated pathway analysis of 
exosomal proteins revealed Integrin and mTOR signaling pathways, both of which are 




Figure 3: Exosomes are nanoscale extracellular vesicles containing specific 
proteins, RNAs and lipids. Proteins include HSP70, 90, GAPDH. Proteins involved in 
synthesis (Alix, ESCRT proteins, TGS101), and membrane associated or 
transmembrane proteins (RAB, Annexins, CAMs, Integrins, Tetraspanins, MHC I and 
II) and other cytosolic proteins. Source: (Cooper et al., 2020) 
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Another abundant component of exosome cargo is miRNAs which regulate gene 
expression. miRNAs in exosomes represent the parental cell type and condition (50). 
Therefore, it is possible to therapeutically alter cell function through directing engineered 
miRNAs into exosomes (60, 61). Many studies proved that exosomes serve to convey 
signals from cell to cell (62-64). The transportation of miRNAs from parental cell to 
target cell results in the miRNA-mediated alteration in gene expression and cellular 
function. Thereby this is an important paracrine signaling mechanism (65), which can be 
used in the regenerative therapy. For example, exosomes have been reported to protect 
against acute kidney injury by altering cellular activities in epithelial/mesenchymal 
transition, matrix remodeling, apoptosis, differentiation, inflammation and repair process 
(66).  
There are several advantages of using MSC exosomes in regenerative medicine 
instead of MSC as a whole cell. The small size of exosomes allows them to circulate 
throughout the body whereas MSCs are too large to pass beyond the capillary bed. A 
cell-derived lipoprotein coat of exosomes protects their cargo from degradation in the 
systemic circulation (49). Exosome delivery can avoid the transfer of mutated or 
damaged cells which might exhibit oncogenic potential and other noxious effects. 
Moreover, the use of exosomes can overcome the scarcity of MSCs because exosomes 
can be harvested multiple times from MSC culture (67). While more research is needed, 
it is certain that MSC exosomes are promising agents as stem cell-based, cell free 
regenerative therapy.   
 1.6 MSC DERIVED EXOSOMES IN BONE REGENERATION 
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MSC exosome-mediated regeneration has received great attention in the past 
decade. For instance, exosomes reduced the morphologic and functional damage of 
glycerol-induced acute kidney injury in SCID mice by inducing proliferation of tubular 
cells (68). BMSC-derived exosomes preserved retinal ganglion cell function and 
promoted axon regeneration through miRNA-dependent mechanisms (69). Treatment of 
MSC exosomes improved cardiac epicardial remodeling and increased left ventricular 
ejection fraction (70). The progression of hypoxic-induced pulmonary hypertension was 
significantly inhibited by intravenous MSC exosome injection (71).  
In regard to bone regeneration, some studies demonstrated MSC exosomes 
have the ability to activate osteogenic differentiation, stimulate angiogenesis, and 
promote bone formation (72-75). miRNAs in hBMSC exosomes such as let-7a are a 
regulator of osteoblast differentiation (76). Many studies demonstrated hBMSC-derived 
exosomes carry miRNAs that contributes to bone regeneration (77-78). In addition to 
miRNAs, there are other important proteins mediating essential signaling pathways in 
bone regeneration. For example, the secretion factors from MSCs, including exosomes, 
can stimulate the expression of RUNX2, a transcription factor that regulates 
osteogenesis by promoting the differentiation of pluripotent stem cells into osteoblasts 
(79). hBMSC exosomes activates multiple signaling pathways such as Akt, Erk1/2 and 
STAT3 to induce angiogenic responses in fibroblasts (80). Wnt pathway plays important 
role in bone repair. hBMSC exosomes activates the Wnt3a-β-catenin pathway and 
induces angiogenic capacity of fibroblast (81). hBMSC exosomes also express high 
level of BMP9, transforming growth factor β1 (TGFβ1), and vascular endothelial growth 
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factor (VEGF), and platelet-derived growth factor (PDGF) (82), all of which are 
important growth factors in osteogenic differentiation and angiogenesis (83-85).  
Previous work in our lab demonstrated the effects of hBMSC exosomes on cell 
proliferation, migration, and cytokine production in vitro. The intensity of hMSC 
migration and proliferation increased as the exosomes dosage increased. From protein 
arrays, various cytokines and growth factors were enriched in the exosomes compare to 
the supernatant of the culture medium. The exosomes also showed anti-inflammatory 
effect, which suppressed IL-6 production in macrophage-like cells, and inhibited 
osteoclast differentiation in vitro. Many small RNAs, such as miR-486, 760, 6087, 7641, 
and 4792, are highly enriched in exosomes compared to total cell lysate.  
1.7 SUMMARY   
 The host inflammatory response triggered by oral microbial biofilm on tooth 
surface causes periodontitis. Complications such as association with systemic disease, 
physical discomfort and negative psychosocial impact due to periodontal deformity can 
remarkably reduce the quality of life of patients. With the limitations of current 
treatments and the expected increase of disease prevalence, new innovative treatment 
which targets the uncontrolled periodontal inflammation is highly desired. While MSC is 
widely recognized, the applications of MSC in regenerative medicine have experienced 
several challenges. Exosomes secreted from MSCs have the advantages to overcome 
the limitations of whole cell delivery while retaining the beneficial regeneration potential 
of MSCs. MSC exosomes may serve as a novel stem cell-based, cell free regenerative 
therapy for treating periodontitis.    
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CHAPTER 2: SPECIFIC AIMS 
 
Progressive periodontal inflammation leads to the destruction of periodontal 
tissues including alveolar bone. Recent studies demonstrated the outcome of stem cell 
exosome therapy in bone regeneration. However, the impact of MSC exosomes in the 
periodontal diseases is still not clear. The overall objective of this study is to explore the 
preventative and therapeutic potential of hBMSC exosomes therapy for periodontitis. 
The first hypothesis was that hBMSC exosomes could prevent periodontal inflammation 
and alveolar bone loss. The second hypothesis was that hBMSC exosomes may 
promote periodontal regeneration after the disease was established.  
2.1 Specific Aims 
The following aims were developed to test our main hypothesis: 
 Specific Aim 1: To determine if hBMSC exosomes would prevent 
periodontal inflammation and alveolar bone loss in ligation-induced periodontitis. 
  Sub-aim 1: To determine the effect of hBMSC exosomes on alveolar bone 
loss via Micro-CT analysis. Periodontitis was induced at rat maxillary molars by suture 
ligation and, concurrently, hBMSC exosomes were injected to gingival papillae every 
week. 3 weeks later, the left and right maxillae of the subjects were harvested, and 
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subsequently analyzed with the standardized micro-CT protocol.  Bone volume and 
alveolar bone level were both quantified.  
  Sub-aim 2: To perform a histological analysis of periodontal tissue from 
the preventative model.  Samples from the harvested maxillae were demineralized and 
sectioned. The slides were then stained with H&E to investigate the morphology and to 
qualitatively show the extent of prevention in disease progression.  
  Sub-aim 3: To perform a histomorphometric analysis of infiltrated 
lymphocytes in gingival subepithelial tissue to determine the effect of exosome on 
periodontal inflammation. Images of gingival tissue from H&E stained sections were 
captured. Lymphocytes in the gingival subepithelial tissue were quantified by specific 
characteristics of lymphocyte.  
 Specific Aim 2: To determine if hBMSC exosomes would promote 
periodontal regeneration in ligation-induced periodontitis.   
  Sub-aim 1: To perform Micro-CT analysis of bone volume and alveolar 
bone level to determine the effect of hBMSC exosomes on periodontal bone 
regeneration. Periodontitis was induced at rat maxillary molars by suture ligating for 3 
weeks. After that, the sutures were removed and weekly exosome injection was started 
for 3 or 6 weeks. The left and right maxillae were harvested, and subsequently analyzed 
with the standardized micro-CT protocol.  Bone volume and alveolar bone level were 
both quantified.  
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Sub-aim 2: To determine the gene expression profiles of periodontal 
tissues during inflammation resolution and tissue regeneration. Gingival papillae were 
dissected from formalin-fixed maxillary samples and RNA was extracted. RT-qPCR was 
performed to analyze the expression of a panel of genes related to inflammation 
activation and resolution.  
2.2 SIGNIFICANCE OF THE STUDY 
 The purpose of these studies was to establish the therapeutic effects of hBMSC 
exosomes in periodontitis with possible further development of an innovative and less 
invasive regeneration therapy. Current periodontal therapies focus mostly on the 
debridement of bacterial pathogens. However, the chronic inflammatory response in the 
hosts is correlated with the susceptibility and severity of the disease. Therefore, safe, 
effective, and efficient therapies to control the excessive inflammatory response can be 
the key of successful treatment for periodontitis. Our previous studies suggested the 
regenerative effects of hBMSC exosomes in calvarial defects. It would be exciting if 
exosome therapy can also be applied to periodontal regeneration and provide a better 
alternative treatment modality which is more time and cost effective and efficacious. Our 
study may lead to novel preventive and therapeutic strategies which would benefit 





CHAPTER 3: METHODS 
 
3.1.  SPECIFIC AIM 1: TO DETERMINE IF hBMSC EXOSOMES WOULD PREVENT 
PERIODONTAL INFLAMMATION AND ALVEOLAR BONE LOSS IN LIGATION-
INDUCED PERIODONTITIS 
Studies in Aim 1 sought to determine if hBMSC exosomes would prevent 
periodontal inflammation and alveolar bone loss in ligation induced periodontitis model 
in rats. hBMSC exosomes are known to be proliferative, chemotactic, anti-inflammatory, 
and anti-resorptive from in vitro studies. With our ultimate goal to develop a more 
effective clinical therapy for periodontal defects, in vivo studies are the reasonable next 
step in progression. We first tested if hBMSC exosomes can exert immunomodulatory 
function to prevent periodontal inflammation and alveolar bone loss.  
20 Male Sprague-Dawley rats (250-300g) were divided into 2 groups: exosome 
treatment and control. The rats were anesthetized with isoflurane. Buprenorphine was 
administered pre-surgically for pain management. 3-0 silk sutures were placed into the 
gingival sulci around the maxillary left second molar (Figure 4). The sutures were left in 
place for three weeks to induce experimental periodontitis. Both groups received weekly 
injections concurrently with suture placement. Injections were administered locally at 
two palatal gingival tissue sites: interdental papillae between 1st and 2nd molars and 




exosomes on weekly injection day: 2.5 µL of exosomes per injection site with 0.33 
µg/µL concentration. Exosomes were harvested from hBMSC culture media through 
sequential ultracentrifugation and quantified by measuring the total protein content 
through BCA assay. Same volume of saline was injected to the control group. After 3 
weeks, rats were euthanized with CO2 and the maxillae were harvested and fixed in 





Figure 4: (A) Rats were laid down on the back and both upper and lower jaws were 
immobilized by fixing a string. (B) 3-0 suture was placed around the maxillary left 
second molar. Suture was first passed through interdentium between second and 
third molar apically. Same suture was passed through another interdentium between 
first and second molar apically. Suture was looped around the neck of the second 
molar and tied firmly using a triple-knot. Excess suture was cut. Source: A) (Muraoka 
et al., 2018), B) (Abe & Hajishengallis, 2013) 
19 
 
3.1.1. AIM 1.1: TO DETERMINE THE EFFECT OF hBMSC EXOSOMES ON 
ALVEOLAR BONE LOSS VIA MICRO-CT ANALYSIS  
The fixed left and right maxillae were scanned by a micro-CT machine, Bruker 
SkyScan 1173. Obtained images were reconstructed using NRecon Reconstruction 
software. Reconstructed images were opened in DATAVIEWER software to align each 
sample with standard parameters shown in Figure 6. Transverse plane of each aligned 
samples was saved for volumetric analysis. Sagittal plane of each aligned samples was 
saved for alveolar bone level analysis.  
For volumetric analysis, the transverse plane images of samples were opened in 




Figure 5: First injection was done on the same day of ligature placement (red). 
Injections (green) were given three times weekly. After 3 weeks, rats were euthanized 





starting from the top layer which is the CEJ of the second molar. Two ROIs, one was 
the area between the first molar and second molar and the other was the area between 
the second molar and third molar, were traced by hand using computer mouse in all 121 
layers as shown in Figure 7. Once the ROI drawing is complete, bone volume was 
quantified with setting threshold within the software. Threshold was found to be the 




Figure 6: Three planes of the sample can be viewed in DATAVIEWER software. (A) 
First, the mesial end of first molar and the distal end of the third molar were aligned 
along with the vertical blue line from the transverse plane at the cementoenamel 
junction (CEJ) of the second molar. (B) Second, the buccal CEJ and the palatal CEJ of 
the second molar were aligned along with the horizontal red line from the coronal 
plane. (C) Third, the mesial CEJ and the distal CEJ of the second molar were aligned 






Figure 7: (A) Bone volume was measured in two different area, zone 1 and zone 2. 
Zone 1 is the area between the first molar and the second molar. Zone 2 is the area 
between the second molar and the third molar. ROI was drawn in the transverse 
plane with the straight tangent line from four roots in each zone as the connecting 
boundaries of the ROI. (B) The process of drawing the ROI of zone 1 was repeated 
approximately every 5 layers. (C) The process of drawing the ROI of zone 2 was 
repeated approximately every 5 layers.  
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bone. Quantitative analysis provided the value of tissue volume (TV), bone volume (BV), 
and a ratio of the two (BV/TV) that represents the percentage of total bone within the 
ROI.    
 
For alveolar bone level analysis, the sagittal plane images of samples were 
opened in CTAn software. Among those sagittal plane images, one or two sagittal plane 
images that the crowns of the first molar, second molar, and third molar were contacted 
to each other were selected. These images were opened in ImageJ software. The CEJ 
midpoints between the first molar and second molar and also between the second molar 





Figure 8: CEJ of the first molar (M1) and the second molar (M2) were connected with 
the straight line. From the midpoint of this line, a perpendicular straight line was 
drawn to alveolar bone crest (ABC). This perpendicular line was measured for the 
alveolar bone level analysis. Same measurement was done between the M2 and the 
third molar (M3).     
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was drawn to the alveolar bone crest (ABC) as shown in Figure 8. This perpendicular 
line was measured to represent the linear bone loss measurement for alveolar bone 
level analysis.   
3.1.2.  AIM 1.2: TO PERFORM HISTOLOGICAL ANALYSIS OF PERIODONTAL 
TISSUE FROM THE PREVENTATIVE MODEL 
After micro-CT analysis, maxillae samples were decalcified in a 14% EDTA 
solution that was pH balanced to 7.2-7.4 with 10N NaOH.  The samples were placed in 
the solution with a stir bar to ensure constant movement and placed in a cold room for 
approximately 16 days.  Once the samples became soft, they were rinsed four times 
with H2O and the samples were temporarily placed back into formalin until ready for 
embedding and sectioning.  With help from the CMMC (Cancer Mouse Models Core, 
Massey Cancer Center, Richmond, VA), the samples were embedded in paraffin blocks 
and sectioned in the sagittal plane from the palatal side so that the roots of the molars 
are visible. The sections were placed on slides and stained with Hematoxylin and Eosin 
(H&E).  The H&E stain helped visualize tissue morphology and allowed for qualitative 
analysis of the samples. Images were captured using Phenochart, a slide visualizer 
supplied by PerkinElmer. 
3.1.3.  AIM 1.3: TO PERFORM A HISTOMORPHOMETRIC ANALYSIS OF INFILTRATED 
LYMPHOCYTES IN GINGIVAL SUBEPITHELIAL TISSUE TO DETERMINE THE EFFECT OF 







Figure 9: (A) 20x resolution images of the periodontal tissue between M1 and M2 
were changed into grayscale image. Threshold was set at the nucleus of epithelial 
layer. Cells which had higher intensity nucleus than the epithelial layer were shown 
in blue. (B) From the origianl 20x resolution images, 50μm depth of subepithelial 
tisue area, ROI, were drawn in yellow line. (C) The longest diameter of nucleus which 
is above threshold within ROI was measured. Another diameter which is the 
perpendicular to the first diameter was also measured. If the ratio of those two 




After obtained the histology images of samples, infiltrated lymphocytes in gingival 
subepithelial tissue were quantified. Images of the periodontal tissue between the first 
molar and the second molar with 20x magnification were captured from the Phenochart 
software. The images were opened in ImageJ software and the infiltrated lymphocytes 
were counted based on the criteria as shown in Figure 9. The first criterion was the cells 
should have a higher nuclear staining than that of gingival epithelial cells. The second 
criterion was that the cells should have smaller nucleus than the epithelial cell nucleus. 
The third criterion was that the ratio of two perpendicular diameters of nucleus than 1.5. 
Cells matched these criteria within the ROI, which includes a subepithelial area 50μm 
from the basal cell layer, were counted as the infiltrated lymphocytes.    
3.2. SPECIFIC AIM 2: TO DETERMINE IF hBMSC EXOSOMES WOULD 
PROMOTE PERIODONTAL REGENERATION IN LIGATION-INDUCED 
PERIODONTITIS 
Studies in Aim 2 sought to determine if hBMSC exosomes would promote 
healing in the ligation induced periodontitis. This regenerative model, an extension of 
the preventive study, simulates the clinical situation when patients come to the clinics 
with existing periodontitis. The hypothesis was that the hBMSC exosomes have 
osteogenic potential and promote periodontal regeneration.   
52 Male Sprague-Dawley rats (250-300g) were divided into 5 groups: baseline (8 
rats), 3-week exosome treatment (11 rats), 3-week control (11 rats), 6-week exosome 
treatment (11 rats), and 6-week control (11 rats). The rats were anesthetized with 
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isoflurane. Buprenorphine was administered pre-surgically for pain management. 3-0 
silk sutures were placed into the gingival sulci around the maxillary left second molar as 
shown in Figure 4. The sutures were left in place for three weeks to induce experimental 
periodontitis. After 3 weeks, rats in the baseline group were euthanized with CO2 and 
the maxillae were harvested and fixed in 10% formalin for further analysis. For all other 
groups, sutures were removed and the first injections were given at the same time. 
Injections were administered locally at two palatal gingival tissue sites: interdental 
papillae between 1st and 2nd molars and between 2nd and 3rd molars of the left 
maxilla. Exosome treatment group received a total of 1.7 µg exosomes on weekly 
injection day: 2.5 µL of exosomes per injection site with 0.35 µg/µL concentration. 
 
Figure 10: Ligature was placed for 3 weeks on the left second molar. Ligature was 
removed after 3 weeks and baseline group was sacrificed at this time point. Other 
groups received injection at the time of ligature removal. 3 week groups are 
sacrificed after 3 weeks of injections. 6 week groups are sacrificed after 6 weeks of 




Exosomes were harvested from hBMSC culture media through sequential 
ultracentrifugation and quantified by measuring the total protein content through BCA 
assay. Same volume of saline was injected to the control group. 3 weeks after the first 
injection, rats from both 3-week exosome treatment and 3-week control groups were 
euthanized with CO2 and the maxillae were harvested and fixed in 10% formalin for 
further analysis. 6 weeks after the first injection, rats from the 6-week exosome 
treatment and 6-week control groups were euthanized with CO2 and the maxillae were 
harvested and fixed in 10% formalin for further analysis. 
3.2.1. AIM 2.1: TO PERFORM A MICRO-CT ANALYSIS OF BONE VOLUME AND 
ALVEOLAR BONE LEVEL TO DETERMINE THE EFFECT OF hBMSC EXOSOMES 
ON PERIODONTAL BONE REGENERATION 
Both left and right maxillae were scanned using a micro-CT machine, Bruker 
SkyScan 1173. Obtained images were reconstructed using NRecon Reconstruction 
software. Reconstructed images were opened in DATAVIEWER software to align each 
sample with standard parameters shown in Figure 6. Transverse plane of each aligned 
samples was saved for volumetric analysis. Sagittal plane of each aligned samples was 
saved for alveolar bone level analysis.  
For volumetric analysis, the transverse plane images of samples were opened in 
CTAn software. Region of interest (ROI) was established in 121 transverse plane layers 
starting from the top layer which was the CEJ of second molar. ROI was the area 
between 8 roots of the molars: two distal roots of the first molar, four roots of the second 
molar, and two mesial roots of the third molar. ROI was traced by hand using computer 
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mouse in all 121 layers as shown in Figure 11. Once the ROI drawing was complete, 
bone volume was quantified with setting threshold within the software. Threshold was 
found to be the lowest acceptable pixel brightness of the bone area. Values above were 
counted as solid bone. Quantitative analysis provided the value of tissue volume (TV), 
bone volume (BV), and a ratio of the two (BV/TV) that represents the percentage of total 
bone within the ROI.     
For alveolar bone level analysis, the sagittal plane images of samples were 
opened in CTAn software. Among those sagittal plane images, one sagittal plane image 
 
Figure 11: (A) Bone volume is measured in the area between 8 roots; 2 distal roots of 
M1, 4 roots of M2, and 2 mesial roots of M3. ROI was drawn in the transverse plane 
with the straight tangent line from each root as the connecting boundaries of the 
ROI. The process of drawing the ROI was repeated approximately every 5 layers.  
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of the midpoint of the second molar was selected. Then, 5 images of every 10th sagittal 
plane image toward both buccal and palatal side from the selected midpoint image were 
selected as well. Total 11 sagittal plane images were selected from each sample. The 
distance between the CEJ of M2 and the ABC in all 11 images were measured in Image 
J software to represent the linear bone loss (Figure 12).  
 
3.2.2 AIM 2.2: TO DETERMINE THE GENE EXPRESSION PROFILES OF 
PERIODONTAL TISSUES DURING INFLAMMATION RESOLUTION AND TISSUE 
REGENERATION  
   
 
 
Figure 12: Horizontal line was drawn at the mesial CEJ of the second molar (M2). 
From the horizontal line, a perpendicular straight line was drawn to alveolar bone 
crest (ABC) between the first molar (M1) and M2. This perpendicular line was 
measured for the alveolar bone level analysis. Same measurement was done from 
the distal CEJ of M2 and the alveolar crest between the M2 and the third molar (M3).     




Periodontal tissues between the first and second molar, and the second and third 
molar were collected with B12 surgical scalpel blade (Figure 13) from the baseline 
group (4), 3-week exosome treatment (5), 3-week control (5), 6-week exosome 
treatment (5) and 6-week control (5). RNA from the periodontal tissue sample was 
extracted with Quick-RNATM FFPE kit (Zymo Research). The tissue samples were 
digested overnight with twice amount of Proteinase K as suggested from the manual at 
55°C. After multiple RNA isolation steps following the manual, RNA was eluted in 15μl 
DNase/RNase-Free Water. Concentration of the RNA was measured with NanoDrop TM 
One/OneC Microvolume UV-Vis Spectrophotometer (Thermo Scientific).  
 
Figure 13: Periodontal Tissue was collected for the gene expression profile 
analysis. Red triangles show where the periodontal tissue was collected from; 
between M1 and M2, and M2 and M3. Collected samples were placed in 10% 
formalin until RNA is extracted.  
31 
 
 High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) was used to 
generate cDNA from the extracted RNA.  The volume contained ~200ng of RNA of each 
sample was calculated. 2.9 μl of RT master mix was prepared on ice by adding, 1.0 μl 
of 10X RT Buffer, 0.4 μl of 25X dNTP Mix (100mM), 1 μl of 10X RT Random Primers, 
and 0.5 μl of MultiScribe TM Reverse Transcriptase. Calculated volume of the RNA 
samples were added along with the RT master mix. If the RNA sample volume needed 
was larger than 7.1 μl which was the maximum amount allowed, only 7.1 μl of the RNA 
sample was added. Total amount all together should be 10 μl. If the total amount was 
smaller than 10 μl, Nuclease-free water was added to make the total amount 10 μl. 
Reverse Transcription (RT) reaction was performed at 25°C for 10 minutes, 37°C for 
120 minutes, and 85°C for 5 minutes. cDNA were stored at -20°C.  
 Target-specific preamplification was performed on the cDNA generated from the 
extracted RNA. 5 μl of cDNA was preamplified in a volume of 30 μl containing 1x 
PerfeCTa® SYBR® Green FastMix® (Quantabio) and 34 primer pairs (Supplementary 
Table 1), 40nM of each primer. Preamplification was performed at 95°C for 3 minutes 
followed by 20 cycles of amplification at 95°C for 20 seconds, 60°C for 3 minutes, and 
72°C for 20 seconds and a final additional incubation at 72°C for 10 minutes. 
Preamplified cDNA samples were stored at -20°C. Preamplified cDNA samples were 
diluted 1:10 with water before performing the Quantitative real-time PCR (qPCR). 
 qPCR was performed in the QuantStudio TM 3 Real-Time PCR System (Applied 
Biosystems) using 10 μl reactions containing 5 μl of 1x PerfeCTa® SYBR® Green 
FastMix® (Quantabio), 400nM of each primer and 2 μl preamplified and diluted cDNA. 
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The same primers were used in the target specific preamplification reaction. qPCR was 
performed at 50°C for 2 minutes and 95°C for 10 minutes followed by 40 cycles of 
amplification at 95°C for 15 seconds and 60°C for 1 minute, followed by a melting curve 
ranging from 60°C to 95°C, 2s per 0.3°C increment. The PCR products were used to 
run gel electrophoresis in order to validate the primer specificity.  2-ΔΔCt method was 
used to calculate relative changes in gene expression. For each animal, the result from 
left side was normalized to that from the right side and the fold change was presented. 
3.3 STATISTICAL ANALYSIS 
All the calculation was done in Excel spreadsheet. The data were analyzed using 
unpaired t-test and one-way analysis of variance (ANOVA), followed by Turkey multiple-
comparison tests. P-values less than 0.05 were considered statistical significance. 


















4.1.  SPECIFIC AIM 1: TO DETERMINE IF hBMSC EXOSOMES WOULD PREVENT 
PERIODONTAL INFLAMMATION AND ALVEOLAR BONE LOSS IN LIGATION-
INDUCED PERIODONTITIS 
 Maxillae samples were analyzed by standardized micro-CT protocols and 
statistical regression. Tissue morphologies were confirmed by histological analysis. 
Infiltrated lymphocytes in the subepithelial tissue were quantified by histomorphometric 
analysis.  
4.1.1. AIM 1.1: TO DETERMINE THE EFFECT OF hBMSC EXOSOMES ON 
ALVEOLAR BONE LOSS VIA MICRO-CT ANALYSIS 
 In the preventative study, periodontitis was induced on the left maxilla and the 
right maxilla remained healthy. The alveolar bone loss analysis was normalized to the 
healthy side of the same animal. Bone volume (BV) was divided by the tissue volume 
(TV) to calculate the percentage of the bone volume in the ROI (BV/TV). BV/TV was 
then normalized to the healthy side BV/TV. The normalized BV/TV in the exosome 
treatment group (0.68, p<0.05) was significantly higher than the control group that was 
0.56, showing significantly less bone loss in the exosome treatment group (Figure 14). 
Alveolar bone level (ABL) was measured by the distance from the CEJ to the ABC in 
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the interproximal space between molars (Figure 8). If the distance is longer, the ABL is 
lower. In opposite, if the distance is shorter, the ABL is higher which means less bone 
loss (Figure 15). ABL was only measured in the interproximal space because it was 
where the most bone loss occurred due to ligature placement as shown in Figure 16. 
The linear distance measurement of the disease side was also normalized to the 
healthy side. The normalized linear measurement in the exosome treatment is smaller 
than the control group (1.34 vs. 1.67, p=0.06), also indicating less bone loss in the 





Figure 14: The volumetric measurements of the exosome treatment group were 
significantly larger than the control group in both the disease side data and the 
normalized data. Alveolar bone loss was significantly reduced in the exosome 










Figure 15: ABL is higher when the linear distance measurement from CEJ to ABC 
shown in blue line is smaller. Higher ABL means less alveolar bone loss. ABL is 
lower when the linear distance measurement from CEJ to ABC shown in yellow line 
is larger. Lower ABL means more alveolar bone loss.  
 
 
Figure 16: (B) Linear distance measurements from CEJ to ABC were done in 9 
different locations. (A) Results showed that the most bone loss happens in the 
interproximal space, Z1 and Z2. The green arrow showed the data points at M2.   
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4.1.2.  AIM 1.2: TO PERFORM HISTOLOGICAL ANALYSIS OF PERIODONTAL TISSUE 
FROM THE PREVENTATIVE MODEL 
 A histological analysis was used to provide insight of the effects exosomes may 
have on tissue morphology. H&E stained histology images of the control group exhibited 
prominent epithelial hyperplasia. In contrast, the exosome treatment group showed less 
increased epithelial cell proliferation (Figure18). Also, there was more severe apical 
migration of junctional epithelium observed in the control group than the exosome 




Figure 17: The linear distance measurements of the exosome treatment group were 
significantly smaller than the control group in both disease side data and the 
normalized data, denoting significantly higher ABL. Alveolar bone loss was 






Figure 18: H&E stained histology sections showed that there were more increased 
epithelial cell proliferation in the control group than the exosome treatment group.  
The epithelial layer of control group is marked with yellow circle. The epithelial layer 






Figure 19: H&E stained histology sections showed that there were more severe 
apical migration of junctional epithelium (JE) in the control group than the exosome 
treatment group.  CEJ is marked with black line. Apical migration of JE of the control 
group is marked with yellow arrow. Apical migration of JE of the exosome group is 
marked with green arrow. 
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4.1.3. AIM 1.3: TO PERFORM A HISTOMORPHOMETRIC ANALYSIS OF INFILTRATED 
LYMPHOCYTES IN GINGIVAL SUBEPITHELIAL TISSUE TO DETERMINE THE EFFECT OF 
EXOSOME ON PERIODONTAL INFLAMMATION 
 Infiltrated lymphocytes in the subepithelial tissue were quantified from the 20x H&E 
stained histology images. Lymphocytes are mostly small in size. Their nucleus appears as 
dense purple and monochromatic round shape. These characteristics made it clear to identify 
infiltrated lymphocytes in subepithelial tissue from the H&E stained histology images (Figure 20). 
In average, there are 2135 infiltrated lymphocytes/mm2 in the control group. Significantly less 
amount of the infiltrated lymphocytes was found in the exosome group, shown in Figure 21 





Figure 20: Red arrow indicates infiltrated lymphocyte. Lymphocytes have round dark 
nucleus surrounded by a narrow rim of cytoplasm. There are clear distinction 
between cytoplasm and nucleus in the color intensity. Most of the lymphocytes are 
small in size.  
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4.2. SPECIFIC AIM 2: TO DETERMINE IF hBMSC EXOSOMES WOULD 
PROMOTE PERIODONTAL REGENERATION IN LIGATION INDUCED 
PERIODONTITIS  
Maxillae samples were analyzed by standardized micro-CT protocols and statistical 
regression. Macrophage related gene expression was analyzed in the periodontal tissue to 




Figure 21: There are significantly less infiltrated lymphocytes in the subepithelial 




4.2.1. AIM 2.1: TO PERFORM A MICRO-CT ANALYSIS OF BONE VOLUME AND 
ALVEOLAR BONE LEVEL TO DETERMINE THE EFFECT OF hBMSC EXOSOMES 





Figure 22: (A) Baseline group has significantly less normalized BV/TV than other 
groups: 3-week exosome treatment group, 6-week exosome treatment group, and 6-
week control group. (B) Baseline group has significantly longer distance from CEJ to 






 In the regenerative study, periodontitis was induced on the left maxilla and the right 
maxilla remained healthy. The alveolar bone loss analysis was normalized to the healthy side of 
the same animal. For bone volume measurement, the differences between the exosome 
treatment group and the control group at both 3-week and 6-week didn’t reach statistical 
significance. Similarly there was no significant difference between the exosome group and the 
control group at both 3-week and 6-week in the alveolar bone level analysis. However, the 
baseline group had significantly less bone volume than the 3-week exosome treatment group 
(p<0.05) and both 6-week groups (p<0.001). Also, there was significantly lower alveolar bone 
level (after normalization to the right side) at the baseline compared to all other four groups 
showing the ligature placement successfully induced periodontitis. The increasing bone volume 
and alveolar bone level showed a natural healing progression with time. (Figure 22).       
4.2.2 AIM 2.2: TO DETERMINE THE GENE EXPRESSION PROFILES OF 
PERIODONTAL TISSUES DURING INFLAMMATION RESOLUTION AND TISSUE 
REGENERATION 
 Periodontal tissues from the regenerative model were collected. cDNA was 
generated from the extracted RNA from the collected periodontal tissues. RT-qPCR was 
done to determine the expression of genes related to inflammation activation and 
resolution. A panel of 34 genes was selected and primers targeting these genes were 
designed (supplementary table 1). The transition of macrophages from M1 phase to M2 
phase is a keystone step in the healing process. Due to time limitation, the expression 
of one gene from each M1 and M2 gene pool were analyzed. Each gene (TNFα and 
TGM2) was selected after the validation of the specificity and efficiency of primers by 
gel electrophoresis (Figure 23) and RT-qPCR. Both TNFα and TGM2 gene expression 
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didn’t show any significant trend during the bone regeneration process (Figure 24) due 

























Figure 23: (A) (B) (C) Primer specificity 
for all 34 primers for the gene of interest 










 method was used to calculate relative changes in gene expression. 
(A) TNFα expression was normalized to β-Actin, (B) TGM2 expression was 
normalized to β-Actin, (C) TNFα expression was normalized to GAPDH, (D) TGM2 
expression was normalized to GAPDH. (A)(B)(C)(D) Disease side was normalized to 






CHAPTER 5: DISCUSSION 
 
 
 In the past decades, exosome therapy has received a lot of attention due to its 
ability to regulate cell and tissue function in the regeneration process. Studies have 
shown that exosomes are osteogenic and anti-resorptive in bone disease (88-90). 
Periodontal disease is caused by the accumulation of bacteria which activates the 
inflammatory response. The continued presence of bacteria results in the destruction of 
periodontal tissue including alveolar bone (91). In this study, we hypothesized that 
hBMSC exosomes prevent alveolar bone loss and have regenerative potential in 
diseased periodontium.  
In the preventative study, we found that hBMSC exosomes reduced periodontal 
inflammation and alveolar bone loss. We were able to set up a standard Micro-CT 
protocol for rat maxillae samples, and therefore reliable and reproducible data were 
generated. Bone volume and alveolar bone level analysis showed the reduction of the 
alveolar bone loss after the exosome treatment. This suggests that the exosomes have 
a preventative effect on the alveolar bone, which is similar to what was shown in other 
degenerative bone diseases (88). In healthy periodontium, junctional epithelium is 
attached onto enamel and protects the tooth surface. With the invasion of bacterial 
pathogenic components, junctional epithelium is detached from the enamel and 
migrates down to the root, which creates pockets (92). Also, the epithelial tissue 
interacts with bacterial pathogens through TLRs producing cytokines and proteinases 
which lead to epithelial proliferation and migration into the inflamed area (93, 94). 
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Imbalanced immune response to the consistent bacterial insults leads to the destruction 
of periodontal tissue, which is associated with the infiltration of lymphocytes into the 
connective tissue (95). We observed lesser extent of epithelial cell proliferation and 
apical migration and reduced amount of infiltrated lymphocytes in the subepithelial 
tissue after the exosome treatment. Overall, this preventative study demonstrated the 
possibility of exosomes to be a protective agent for periodontal disease with the ability 
of regulating inflammatory response.  
Histomorphometric analysis was used instead of immunohistochemistry to 
quantify the infiltrated lymphocytes in this study because we encountered technical 
difficulties finding antibodies for lymphocytes. We can continue to try different antibodies 
to detect and visualize the lymphocytes in the future study to confirm the findings in our 
current study.   
      In the regenerative model, our data didn’t support that hBMSC exosomes promote 
the alveolar bone regeneration. Many factors may be associated with the results. For 
example, the dosage of exosomes should be further explored. We observed the efficacy 
of the exosomes in the preventive study. The main difference between the two models 
is the timepoint of the injection of hBMSC exosomes. Administering of hBMSC 
exosomes starting at the healthy stage or the early stage of immune response may 
have been enough to suppress the inflammatory response and subsequently prevent 
alveolar bone destruction, however, higher exosome concentration may be needed to 
enhance the tissue repair in the presence of severe periodontitis. The fact that the 
regenerative effect of exosomes is dose dependent has also been shown in other bone 
diseases (96-98). Also, different methods to deliver the exosomes can be tested in the 
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future. In this study, we used subgingival injection because it is easy and less invasive. 
However, the amount of exosomes that can be delivered through this method is limited 
due to the small injection volume (~2 μl/site). Excessive liquid volume will lead to tissue 
necrosis. It is also not clear how long the exosomes can stay at the disease site after 
the injection. Other studies also indicated the importance of delivery strategy. Chew et 
al. demonstrated that exosome loaded in collagen sponge promoted regeneration 
potential (98).  
The self-regeneration of periodontium was appreciated in our regenerative model, 
which was shown by the increased BV/TV values at 6-week comparing to baseline. This 
phenomenon has also been documented in literature (99, 100). To explore the 
important genes that are involved in the inflammation resolution and tissue regeneration 
process, we designed a panel of primers targeting genes involved in the transition of 
macrophages (M1-M2), key enzymes in the metabolism of lipidic inflammation 
resolution products, cytokines and growth factors. Periodontal tissue was collected from 
the formalin fixed maxillae sample to extract RNA. RNA integrity was assessed prior to 
further process. In order to obtain reliable data from the downstream research process, 
RIN number usually should be above 7. Our extracted RNA showed RIN numbers 
between 2 and 3, indicating that formalin fixation broke down RNA molecules and 
modified RNA. The poor RNA quality might contribute to the large variance that we saw 
in the PCR results. Other studies suggested that using formalin free fixative, such as 
PAXgene Tissue System (101) and cryopreservation (102), can improve the RNA 
quality to enhance the comparability and reliability of RT-PCR experiments. Even 
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though our preliminary gene expression results didn’t lead us to any conclusion yet, 



















CHAPTER 6: CONCLUSION 
 
 Current traditional periodontal disease treatments focus mainly on mechanical 
debridement. Adjunctive treatments such as systemic antibiotics are associated with 
serious complications and antibiotic resistance. It is important to direct route of our 
journey in developing future preferential therapy to harness the host immune system 
modulation strategy since the destruction of periodontal tissues was done directly by 
host immune response. Cell-based treatments using MSCs are thought to be an 
alternative novel therapy due to its pleiotropic effects. Problem of scarcity and possible 
oncogenic potential with utilizing MSCs can be solved with hBMSC exosomes as they 
convey the regenerative factors including specific nucleic acids and proteins from 
parental cells.  
 Our study evaluated the protective and regenerative potential of hBMSC 
exosomes in the application of periodontal regeneration in ligature-induced 
experimental periodontitis in rats. hBMSC exosomes significantly reduced periodontal 
inflammation and alveolar bone loss in an experimental periodontitis model. When 
applied as a therapeutic agent, hBMSC exosomes did not show statistically superior 
effects compared to control. Interestingly, natural inflammation resolution and tissue 
regeneration was observed in the study, which may be worthwhile for further research 
to understand the underlying mechanism. Overall, this study suggested that hBMSC 
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      Supplementary Table 1.  Primers used for RT-qPCR detection in this study 
  Gene Forward Primer (5'->3') Reverse Primer  (5'->3') Product Length Tm (C) 
Housekeeping Gene GAPDH AGTGCCAGCCTCGTCTCATA GGTAACCAGGCGTCCGATAC 77 60 
  Actin-b CGCGAGTACAACCTTCTTGC CGTCATCCATGGCGAACTGG 70 60 
  Hprt1 TCCTCCTCAGACCGCTTTTC ATCACTAATCACGACGCTGGG 78 60 
M1: pro-inflammatory IL1b TAGCAGCTTTCGACAGTGAGG TCTGGACAGCCCAAGTCAAG 100 60 
  IL6 CATTCTGTCTCGAGCCCACC GCTGGAAGTCTCTTGCGGAG 91 60.5 
  TNFa ATGGGCTCCCTCTCATCAGT TGGTTTGCTACGACGTGGG 100 60 
  IL23 AAAAGTGACGTGCCCCGTAT TGCAAACAGAACTGGCTGTTG 80 60 
  IL12b GAGGCCCAGCAGCAGAATAA GGTGGGTCCGGTTTGATGAT 77 59 
  IL12a GCCTGCTTACCACTGGAACT GCAGGCAGCTCCCTCTTATT 85 59 
  IL17a GGAGAATTCCATCCATGTGCC ATGAGTACCGCTGCCTTCAC 76 60 
  IL17b CACACAGCCTGCTCTTCCTT GCCCCTTCCTTTTGCCTTTG 84 60 
  IL17c ACTGCCACTGTGATGTGTCT AATGGGGGATCTTGGTGGGT 71 60 
  IL17d CCCCACCTCCTAACAAGTCTG GAGGGCATCCAGACCAGTGTC 70 60 
  IL17f TTCTATTGCGTGACCCGGAG GGAGCCCTTCATGCTGGATT 87 60 
M2: inflammation resolution IL10 TGCGACGCTGTCATCGATTT AGACACCTTTGTCTTGGAGCTT 96 60 
  TGFb1 CTGCTGACCCCCACTGATAC AGCCCTGTATTCCGTCTCCT 94 60 
  ARG1 ACAAGACAGGGCTACTTTCAGG TGCCGTGTTCACAGTACGAG 95 60 
  MRC1 TCAACTCTTGGACTCACGGC GAACGGAGATGGCGCTTAGA 83 59 
  IL1ra TCCTTCTCATCCTTCTGTTTCGT CCCAGATTCTGAAGGCTTGC 87 59 
  IL4 AACAAGGAACACCACGGAGA TGTTCTTCAAGCACGGAGGT 98 59 
  IL13 GATCCACATCTCCCCCTGTG GGGAAGTCTTCTGGTCTTGTGT 78 59 
 
TGM2 GTTCCTGAAGGACCGTAGCC CATTGCAGTTGACCATGCCG 89 60 
  Anxa1 GGAAGACAAGGCAATACAAAGATAC ACATATTCCTGCTCTTGCTTTTCA 100 58 
  Tnfaip3/A20 TGCTACGACACTCGGAACTG GTACTGAAGTCCACTCCGGG 93 59 
  ALOX15 GGTTGGTTGGACAGCATGGA AATTCTGCTTCCGAGTCCCG 73 60 
  ALOX15B GACCGTGAAAGACTTGGACCT TCAGCTCTGTAAACGCAGACT 92 59 
  ALOX5 GGCGGTCGCGACTCCTAT GCCTGTATTTGCGCTTCTCG 85 60 
  Edil3/Del1 CTGTCAGGATTGGCGGATGA TCTGATGCAACCTCCACAACA 92 59 
  Ptgs2/Cox2 TCCCATGGGTGTGAAAGGAAA CTTGGGGATCCGGGATGAAC 95 60 
Osteoclast Differentiation Tnfsf11/RANKL GAGCGCAGATGGATCCTAACA GTCGAGTCCTGCAAACCTGT 97 60 
  Tnfrsf11b/OPG AGAGAAGCACCTAGCACTGG GTCCAAGAACACCAGGAGTG 99 59 
BET BRD2 GTGACTCCCCACAAGCTCC ATCCTTTTCCCTGGTGCTGC 83 60 
  BRD3 CTAGCGTCTCAGAGTGCCT TCTCAATCTTGTCCCAGGGC 82 58 
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